Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells  by Sakaguchi, Masanobu et al.
Role and Regulation of STAT3 Phosphorylation at
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Masanobu Sakaguchi1, Masahiro Oka1, Tetsushi Iwasaki2, Yasuo Fukami2 and Chikako Nishigori1
The transcription factor signal transducer and activator of transcription 3 (STAT3) has two important phos-
phorylation sites, Tyr705 and Ser727, for its activation. Ser727 phosphorylation has been considered to be a
secondary event after Tyr705 phosphorylation. In this study, the role and regulation of Ser727 phosphorylation
in STAT3 in melanocytic cells were examined. STAT3 was phosphorylated on Ser727 in the absence of Tyr705
phosphorylation in melanocytes. 12-O-tetradecanoylphorbol-13-acetate-induced increase in cell survival
activity and nuclear translocation of STAT3 was associated with Ser727 phosphorylation. Ser727 was
constitutively phosphorylated in all melanoma cell lines examined irrespective of Tyr705 phosphorylation.
The possible involvement of Ser727 phosphorylation in STAT3 in cell survival activity and nuclear translocation
of STAT3 in melanocytes was demonstrated also in melanoma cells. The constitutive Ser727 phosphorylation in
melanoma cells was partially mediated by the B-Raf–MEK–ERK1/2 pathway. Immunohistochemical studies on
specimens of primary lesions of acral lentiginous melanoma revealed that Ser727 phosphorylation precedes
Tyr705 phosphorylation in the early stages of melanoma progression. Our results indicate that Ser727
phosphorylation on STAT3 is not necessarily a secondary event after Tyr705 phosphorylation and suggest that it
has a role in the regulation of cell survival activity and nuclear translocation of STAT3 in melanocytic cells.
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INTRODUCTION
Malignant melanoma arises from the transformation and
proliferation of melanocytes that are present in the basal layer
of the skin epidermis and are responsible for the production
of the skin pigment melanin. Although there have been
significant basic scientific advances in understanding of the
tumor biology of melanoma (Smalley and Herlyn, 2005;
Hocker et al., 2008; Lopez-Bergami et al., 2008; Russo et al.,
2009), the exact mechanism for melanomagenesis has not
been fully elucidated.
The transcription factor signal transducer and activator of
transcription 3 (STAT3) is activated in response to various
growth factors, hormones, and cytokines, and has an
important role in their signaling (Darnell, 1997). When these
ligands bind to the specific transmembrane STAT3 receptor,
STAT3 becomes activated by JAK-mediated tyrosine phos-
phorylation of a critical tyrosine residue (Tyr705) and
dimerizes through reciprocal Src homology 2–phosphotyro-
sine interaction. The dimeric STAT3 translocates to the
nucleus, where it binds to consensus STAT3 binding
sequences within the promoter region of target genes and
thereby activates their transcription (Darnell, 1997). It is
generally thought that tyrosine phosphorylation regulates the
dimerization of STATs as an essential prerequisite for the
establishment of a classical JAK–STAT3 signaling pathway
and Tyr705 phosphorylation has been regarded as a
characteristic of STAT3 activation (Bowman et al., 2000;
Decker and Kovarik, 2000; Levy and Lee, 2000; Aggarwal
et al., 2009). However, the STAT3 molecule contains a
second phosphorylation site, Ser727, within its C-terminus.
Although it has been suggested that Ser727 phosphorylation
is a secondary event after Tyr705 phosphorylation required
for the maximal transcriptional activity of STAT3 (Wen et al.,
1995), it is now becoming clear that regulation of STAT3
function by Ser727 phosphorylation is more complex than
originally expected (Bowman et al., 2000; Decker and
Kovarik, 2000; Aggarwal et al., 2009).
In normal cells, the duration of STAT3 activation is
temporary, usually lasting from a few minutes to several
hours (Bromberg and Chen, 2001). In contrast, constitutive
activation of STAT3, as demonstrated by detection of Tyr705
phosphorylation, has been observed in many kinds of
tumors including melanomas (Niu et al., 2002; Messina
et al., 2008; Oka et al., 2009). We have recently demon-
strated that constitutive phosphorylation of Tyr705 has an
important role in melanoma growth and this activation is
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negatively regulated by protein-kinase-C–activated tyrosine
phosphatase(s) (Oka et al., 2009). In the present study, we
examined the role and regulation of Ser727 phosphorylation
in STAT3 in melanocytic cells. We showed that STAT3 is
constitutively phosphorylated on Ser727 irrespective of
Tyr705 phosphorylation in normal melanocytes and melano-
ma cells and that the Ser727 phosphorylation is associated
with cell survival activity and nuclear translocation of STAT3
in these cells. We also showed that the constitutive Ser727
phosphorylation is in part regulated by B-Raf-extracellular–-
regulated kinase (ERK) kinase (MEK) in melanoma cells. In
addition, we demonstrated that Ser727 is frequently phos-
phorylated in the absence of Tyr705 phosphorylation in
melanoma cells in vivo, particularly in in situ lesions of acral
lentiginous melanoma (ALM) tissues.
RESULTS
Phosphorylation state of Ser727 in STAT3 in human
melanocytes and melanoma cells
To determine the phosphorylation state of Ser727 in STAT3 in
melanocytic cells, the expression levels of STAT3 phosphory-
lated on Ser727 (pS-STAT3) as well as on STAT3 phosphory-
lated on Tyr705 (pY-STAT3) in melanocytes and seven
human melanoma cell lines were examined by western
blotting (Figure 1). In cultured quiescent melanocytes, low
levels of pS-STAT3 but not pY-STAT3 were detected. pS-
STAT3 was expressed in all the seven melanoma cell lines,
whereas pY-STAT3 level was not detected in two melanoma
cell lines, WM35 and WM39 cells.
Association of Ser727 phosphorylation with cell survival
activity and nuclear translocation of STAT3 in melanocytes
We have previously shown that the tumor-promoting phorbol
ester 12-O-tetradecanoylphorbol-13-acetate (TPA) has an
anti-apoptotic effect on growth factor deprivation-induced
apoptosis in melanocytes (Oka et al., 2004). To examine the
possible involvement of Ser727 phosphorylation in the
protection against growth factor deprivation-induced apop-
tosis in melanocytes, the effects of TPA on pS-STAT3
expression and on growth factor deprivation-induced apop-
tosis in melanocytes was examined (Figure 2a). In quiescent
melanocytes, ERK1/2 was phosphorylated slightly as de-
scribed previously (Oka et al., 2007). Upon treatment with
TPA, the expression of pS-STAT3 was enhanced in a time-
dependent manner concomitant with an increase in ERK1/2
activity within 60minutes of treatment. Thereafter, both the
pS-STAT3 expression level and ERK1/2 activity decreased to
basal levels by 24 hours. The increase in the expression of pS-
STAT3 was associated with the increase in cell survival
activity of the melanocytes (Figure 2b).
To determine the effect of TPA on the cellular localization
of pS-STAT3 in melanocytes, immunofluorescent analysis
was carried out (Figure 2c and d). In quiescent cells, very low
levels of pS-STAT3 were detected in the nucleus (Figure 2c,
pS-STAT3, 0 hours). Total STAT3 was localized mainly
in the cytoplasm (Figure 2d, t-STAT3, 0 hours). At 1 hour
after TPA treatment, nuclear pS-STAT3 as well as total
nuclear STAT3 increased (Figure 2c, pS-STAT3, 1 hour and
Figure 2d, t-STAT3, 1 hour). TPA-induced increase in nuclear
pS-STAT3 and total nuclear STAT3 was confirmed also by
western blotting (Supplementary Figure S1 online). In
addition, western blotting revealed that TPA increases
cytoplasmic pS-STAT3. Data from immunofluorescent and
western blot analyses suggest that TPA induces Ser727
phosphorylation of cytoplasmic STAT3 and that a part of
the increased cytoplasmic pS-STAT3 actively translocates
into the nucleus.
Regulation of the constitutive phosphorylation of Ser727 in
STAT3 in melanoma cells
We next focused on Ser727 phosphorylation in melanoma
cells. It has been reported that several kinases, such as ERK1/
2 (Chung et al., 1997), p38 mitogen-activated protein kinase
(Gollob et al., 1999), c-Jun N-terminal kinase (Lim and Cao,
1999), protein kinase C (Jain et al., 1999; Aziz et al., 2007),
mammalian target of rapamycin (Yokogami et al., 2000), and
cyclin-dependent kinase 5 (Fu et al., 2004), mediate Ser727
phosphorylation in STAT3. To examine whether these kinases
are involved in the constitutive phosphorylation of Ser727 in
STAT3 in melanoma cells, the effects of inhibitors of these
kinases on the phosphorylation state of Ser727 in four
melanoma cell lines, WM35, WM39, WM98-1, and
WM1205Lu, were investigated. U0126, which inhibits
ERK1/2 through MEK inhibition, reduced the phosphorylation
of pS-STAT3 by approximately 30–50% in three cell lines,
WM39, WM98-1, and WM1205Lu, concomitant with
inhibition of ERK1/2 activity (Figure 3a). Conversely, inhibi-
tors of p38 mitogen-activated protein kinase (SB203580), c-
Jun N-terminal kinase (SP600125), protein kinase C
(GF109203X), mammalian target of rapamycin kinase (rapa-
mycin), and cyclin-dependent kinase 5 (roscovitine) did not
affect the phosphorylation level of pS-STAT3 in these four cell
lines (Supplementary Figure S2 online). U0126 treatment
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Figure 1. Ser727 is constitutively phosphorylated in signal transducer and
activator of transcription 3 (STAT3) in human melanocytes and melanoma
cells. Whole-cell extracts from quiescent melanocytes and seven human
melanoma cell lines, WM35, WM39, WM98-1, WM115, WM164, WM239-
A, and WM1205Lu, were prepared, and the phosphorylation levels of STAT3
phosphorylated on Ser727 (pS-STAT3) as well as of STAT3 phosphorylated on
Tyr705 (pY-STAT3) were determined by western blotting using anti-pS-STAT3
and anti-pY-STAT3 antibodies, respectively. The expression levels of total
STAT3 (t-STAT3) and b-actin were also examined. The results shown are
representative of three independent experiments.
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increased pY-STAT3 expression in WM98-1 and WM1205Lu
cells (Figure 3a). The mechanism of U0126-induced upregu-
lation of pY-STAT3 expression in these cells is currently
unknown.
It has been shown that an activating mutation in B-Raf
(V600E) frequently occurs in melanoma cells (Davies et al.,
2002), leading to activation of the MEK–ERK1/2 pathway
(Heath et al., 2011). To examine whether an activating
mutation of B-Raf is involved in the MEK–ERK1/2-induced
Ser727 phosphorylation in STAT3 in melanoma cells, the
effect of the inhibitor of active B-Raf (V600E) kinase,
PLX4720 (Tsai et al., 2008), on the phosphorylation state of
Ser727 in the four melanoma cell lines WM35, WM39,
WM98-1, and WM1205Lu was examined (Figure 3b). Of the
four melanoma cell lines, WM35, WM39, and WM1205Lu
cells harbor the B-Raf V600E mutation (Smalley et al., 2008),
while the B-Raf V600E mutation has not been examined in
WM98-1 cells. As shown in Figure 3b, inhibition of active B-
Raf kinase reduced pS-STAT3 expression in all the four
melanoma cell lines, indicating that Ser727 phosphorylation
in STAT3 is partly mediated by the B-Raf–MEK–ERK1/2
pathway in melanoma cells.
Role of Ser727 phosphorylation in nuclear translocation of
STAT3 in melanoma cells
To examine the relationship between the cellular localization
of STAT3 and Ser727 phosphorylation in melanoma cells, the
effect of U0126 on pS-STAT3 as well as total STAT3 was
investigated by immunofluorescent analysis using WM39
cells containing pS-STAT3 but not pY-STAT3. pS-STAT3 was
exclusively localized in the nucleus of the cells (Figure 3c,
pS-STAT3, 0 hours). Total STAT3 was detected strongly in the
nucleus and weakly in the cytoplasm (Figure 3d, t-STAT3,
0 hours). The treatment of cells with U0126 resulted in a
decrease in nuclear pS-STAT3 as well as in total nuclear
STAT3 concomitant with an increase in total cytoplasmic
STAT3 (Figure 3c and d, pS-STAT3 and t-STAT3, 2 hours),
suggesting that dephosphorylated nuclear STAT3 translocates
into the cytoplasm.
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Figure 2. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cell survival activity and nuclear translocation of signal transducer and activator of
transcription 3 (STAT3) are associated with Ser727 phosphorylation in melanocytes. (a) Quiescent melanocytes were treated with 100 nM TPA. The expression
levels of STAT3 phosphorylated on Ser727 (pS-STAT3), STAT3 phosphorylated on Tyr705 (pY-STAT3), total STAT3 (t-STAT3), phosphorylated extracellular
signal–regulated kinase (ERK)1/2 (p-ERK1 and p-ERK2), total ERK1/2 (t-ERK1 and t-ERK2), and b-actin were determined at the indicated time as in Figure 1.
(b) Quiescent melanocytes were treated with either 0.1% DMSO (control) or 100 nM TPA for 24 hours, and cell survival activity was assessed. Data are expressed
as percentage of control (DMSO) and are shown as mean±SD, (n¼ 3; **Po0.01). (c, d) Quiescent melanocytes were treated with 100 nM TPA for 1 hour. The
localization of (c) pS-STAT3 as well as (d) total STAT3 before (0 hours) and after (1 hour) the treatment was examined by immunofluorescent analysis.
Bar¼20 mm.
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It has been shown that activation (Tyr705 phosphoryla-
tion) of STAT3 in some melanoma cell lines relies on JAK
(Kreis et al., 2007). To exclude the possibility of the
involvement of Tyr705 phosphorylation in the nuclear
translocation of STAT3, the effects of a JAK inhibitor, JAK
inhibitor I, on the cellular localization of STAT3 in WM39
cells were examined. Cellular localization of pS-STAT3 as
well as of total STAT3 was not affected either at 1 hour (data
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Figure 3. Regulation and role of Ser727 phosphorylation in melanoma cells. Melanoma cells were treated with (a) either 25 mM U0126 for 2 hours or (b) 1 mM
PLX4720 for 3 hours. (a and b, left) The expression levels of signal transducer and activator of transcription 3 (STAT3) phosphorylated on Ser727 (pS-STAT3),
STAT3 phosphorylated on Tyr705 (pY-STAT3), total STAT3 (t-STAT3), extracellular signal–regulated kinase (ERK)1/2, total ERK1/2, and b-actin in treated
melanoma cells were determined by western blotting as in Figure 1. (a and b, right) The relative amount of pS-STAT3/t-STAT3 in treated cells was calculated.
The ratio of pS-STAT3/t-STAT3 in DMSO-treated (control) cells is represented as 1. Data are shown as mean±SD (n¼3; **Po0.01). (c, d) WM39 cells were
treated with 25mM U0126 for 2 hours and the localization of (c) pS-STAT3 as well as (d) t-STAT3 before (0 hours) and after (2 hours) the treatment were examined
by immunofluorescent analysis. Bar¼ 20mm.
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not shown) or at 3 hours after JAK inhibitor I treatment in
WM39 cells (Supplementary Figure S3 online), indicating that
the JAK–pY-STAT3 pathway is not involved in the nuclear
translocation of STAT3.
Association of Ser727 phosphorylation with cell survival
activity in melanoma cells
The effect of the small interfering RNAs (siRNAs) of STAT3 on
cell survival activity was examined in WM39 cells. Knock-
down of STAT3 by siRNAs in WM39 cells significantly
reduced the expression levels of total STAT3 as well as of pS-
STAT3 concomitant with a decrease in cell survival activity
(Figure 4a and b). As the majority of STAT3 is present as pS-
STAT3 in WM39 cells, these results indicate that the
expression level of pS-STAT3 is associated with the cell
survival activity of melanoma cells. The association between
the expression level of pS-STAT3 and the cell survival activity
of melanoma cells was also shown in an experiment in which
the effects of U0126 on cell survival activity of melanoma
cells were examined (Figure 4c). U0126 treatment signifi-
cantly reduced the cell survival activity of all the four
melanoma cell lines examined.
Detection of DNA-binding activity of pS-STAT3 in melanoma
cells and melanocytes
To determine whether pS-STAT3 has DNA-binding activity in
the absence of Tyr705 phosphorylation, the effects of U0126
or TPA treatment on the DNA-binding activity of STAT3 in
WM39 melanoma cells and melanocytes, respectively, were
investigated. Significant changes in the DNA-binding activity
of STAT3 between non-treated and treated cells were not
detected in either WM39 cells or melanocytes (Supplemen-
tary Figure S4 online).
Expression levels of pS-STAT3 and pY-STAT3 in melanoma
tissues
Finally, the expression levels of pS-STAT3 and pY-STAT3
were examined in 15 sections of primary lesions of ALM,
which is the most common clinical type in Japan and has
clear in situ lesions in the early stages of progression (Seiji
et al., 1983) (Figure 5 and Table 1). The 15 sections were
divided into two groups by histological progression, i.e., in
situ only group (nine cases) and in situ plus dermal invasion
group (six cases). In the nine cases of the in situ only group,
pS-STAT3 but not pY-STAT3 was detected mainly in the
nucleus in some but not all of the melanoma cells in five
cases. Neither pS-STAT3 nor pY-STAT3 was detected in the
remaining four cases of in situ only group. In the six cases of
the in situ plus dermal invasion group, pS-STAT3 was
detected in some but not all melanoma cells, mainly in the
nucleus, in both in situ and dermal invasive lesions in all
cases, while pY-STAT3 was detected in some cells, mainly in
the nucleus, in only dermal invasive lesions in four cases.
DISCUSSION
In the case of polypeptide ligand-induced STAT3 activation
in cells, STAT3 translocates to the nucleus after being
phosphorylated at Tyr705, followed by phosphorylation at
Ser727. Thus, it has been assumed that Ser727 phosphoryla-
tion is a secondary event after Tyr705 phosphorylation, and
Tyr705 phosphorylation has been regarded as a characteristic
of STAT3 activation. However, we have found in this study
that Ser727 is constitutively phosphorylated in melanocytes
and melanoma cells irrespective of Tyr705 phosphorylation.
These results suggest that the regulation mechanism of Ser727
phosphorylation in melanocytic cells is different from that of
polypeptide ligand-induced Ser727 phosphorylation. We
have shown that Ser727 is constitutively phosphorylated in
the absence of Tyr705 phosphorylation in melanocytes and
that TPA increases the phosphorylation level of Ser727
without inducing Tyr705 phosphorylation. Thus, it is evident
that TPA-induced Ser727 phosphorylation in melanocytes is
not a secondary event after Tyr705 phosphorylation, although
the detailed mechanism of TPA-induced Ser727 phosphor-
ylation remains unclear. On the other hand, we have shown
that constitutive Ser727 phosphorylation in melanoma cells is
partially regulated by the B-Raf–MEK–ERK1/2 pathway. As the
Pro-Met-Ser727-Pro sequence at the C-terminus of STAT3
(Wen et al., 1995) has been identified as a phosphorylation
site of ERKs, Pro-X-Ser-Pro (Gonzalez et al., 1991), our results
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suggest that activating mutations in B-Raf contribute to
Ser727 phosphorylation in STAT3 in melanoma cells through
the MEK–ERK1/2 pathway.
The constitutive phosphorylation of Ser727 in melanocytes
and melanoma cells suggests that Ser727 phosphorylation has
a role in these cells. The close association of the pS-STAT3
expression level with the nuclear translocation of STAT3 and
cell survival activity suggests that Ser727 phosphorylation is
involved in the regulation of cell survival activity and nuclear
translocation of STAT3 in melanocytic cells. We have
previously shown that Tyr705 phosphorylation is important
for melanoma growth, suggesting that it is likely that both pS-
STAT3 and pY-STAT3 have a role either synergistically or
independently in survival or growth of melanoma cells.
However, our present study suggests that pS-STAT3 may have
a role in cell survival in melanocytes in the absence of pY-
STAT3. Collectively, we consider that the function of pS-
STAT3 in the enhancement of cell survival activity in
melanocytes is active during melanomagenesis, while the
function of pY-STAT3 in survival and growth appears in
melanoma cells, and works in addition to that of pS-STAT3.
Our immunofluorescent analysis data indicate the presence of
small amounts of unphosphorylated STAT3 in the nucleus in
melanocytes and melanoma cells. The role of the unpho-
sphorylated STAT3 in gene regulation in these cells remains to
be clarified.
As STAT3 is a transcription factor and pS-STAT3 is
localized mainly in the nucleus, it was assumed that the
stimulatory effect of pS-STAT3 on cell survival activity in
melanocytic cells is mediated by its transcriptional activity
after DNA binding. It has been shown that Ser727 phosphor-
ylation regulates the transcriptional activity of STAT3
H&E pS-STAT3 pY-STAT3
Pt 1
Pt 2
Pt 3
Pt 10
Pt 11
Figure 5. Expression of signal transducer and activator of transcription 3 (STAT3) phosphorylated on Ser727 (pS-STAT3) and STAT3 phosphorylated on
Tyr705 (pY-STAT3) in primary acral lentiginous melanoma (ALM) tissues. Sections from ALM patients were immunostained with antibodies against pS-STAT3
and pY-STAT3. The yellow and black arrows indicate positive immunolocalization of pS-STAT3 and pY-STAT3, respectively. Representative results of three
patients (Pt 1, Pt 2, and Pt 3) with ALM in situ and two patients (Pt 10 and Pt 11) with ALM containing dermal invasive lesions as well as in situ lesions are shown
(bar¼ 100 mm). Patient numbers correspond to those in Table 1. Insets show magnified images of pS-STAT3- or pY-STAT3-positive cells in dotted squares,
respectively. Atypical melanocytes stain for pS-STAT3 but not pY-STAT3 (Pt 1, Pt 2, and Pt 3). Melanoma cells in the dermis stain for both pS-STAT3 and
pY-STAT3 (Pt 10 and Pt 11). H&E, hematoxylin and eosin.
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positively (Schuringa et al., 2001; O’Rourke and Shepherd,
2002; Aziz et al., 2010) or negatively (Jain et al., 1999) in the
presence of Tyr705 phosphorylation. However, it has not
been determined whether pS-STAT3 has DNA-binding
activity in the absence of Tyr705 phosphorylation. We
attempted to detect pS-STAT3-dependent but pY-STAT3-
independent DNA-binding activity by comparing the activity
between U0126-treated and U0126-untreated WM39 cells
and between TPA-treated and TPA-untreated melanocytes
using the TransAM STAT3 transcription factor assay kit, but
no significant difference in DNA-binding activity was
detected in either case (Supplementary Figure S4 online).
This does not exclude the possibility that pS-STAT3 binds to
DNA, leading to transcriptional regulation of genes. The
principle of the kit is that it contains a 96-well plate with
immobilized oligonucleotides encoding a pY-STAT3 con-
sensus site (50-TTCCCGGAA-30) (Zhong et al., 1994; Darnell,
1997) and the active form of STAT3 contained in the cell
extract should specifically bind to these oligonucleotides.
Thus, if pS-STAT3 binds to a different site(s) from the
pY-STAT3 consensus site, the DNA-binding activity of
pS-STAT3 cannot be detected by the kit. From the data
obtained in the present study, including Supplementary
Figure S4 online, it is considered that pS-STAT3 has its own
target genes that have binding site(s) for pS-STAT3 but not
for pY-STAT3.
In accordance with in vitro data, immunohistochemical
studies on specimens of primary lesions of ALM revealed that
pS-STAT3 is frequently expressed in the absence of Tyr705
phosphorylation in melanoma cells in in situ lesions of ALM,
and that pY-STAT3 as well as pS-STAT3 is expressed in
dermal invasive lesions of ALM. These data raise two
possibilities regarding the roles of Ser727 and Tyr705
phosphorylation. One is that each of Ser727 phosphorylation
and Tyr705 phosphorylation has its own role and affects
different functions of STAT3. In this case, it is interesting to
consider whether Ser727 phosphorylation has a role in the
acquisition of autonomous growth in the early stages of ALM
progression, especially in in situ lesions, and whether Tyr705
phosphorylation acts as a molecular switch to the dermal
invasion by melanoma cells. The other possibility is that
Ser727 phosphorylation and Tyr705 phosphorylation act
synergistically on STAT3 functions.
To summarize, our results indicate that Ser727 phosphor-
ylation on STAT3 is not necessarily a secondary event after
Tyr705 phosphorylation and that Ser727 phosphorylation has
its own role and regulation mechanism in melanocytic cells.
Elucidation of the detailed regulation mechanism of Ser727
phosphorylation and the role of pS-STAT3 may lead to a
better understanding of melanomagenesis.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies against STAT3 and pS-STAT3 were from Santa Cruz
Biotechnology (Santa Cruz, CA). An antibody against pY-STAT3 was
obtained from Cell Signaling Technology (Beverly, MA). Antibodies
against ERK1/2 and phospho-ERK1/2 were purchased from Promega
(Madison, WI). An antibody against b-actin was from Epitomics.
Table 1. Summary of expression of pS-STAT3 and pY-STAT3 in ALM tissues
% Of pS-STAT3-positive melanoma
cells1 % Of pY-STAT3-positive melanoma cells1
Patient number Histological progression Epidermis Dermis Epidermis Dermis
1 In situ only 64±46 0 0 0
2 In situ only 52±30 0 0 0
3 In situ only 74±23 0 0 0
4 In situ only 32±8.4 0 0 0
5 In situ only 54±21 0 0 0
6 In situ only 0 0 0 0
7 In situ only 0 0 0 0
8 In situ only 0 0 0 0
9 In situ only 0 0 0 0
10 In situþ dermal invasion 64±25 16±11 0 54±21
11 In situþ dermal invasion 60±35 20±10 0 38±13
12 In situþ dermal invasion 72±29 36±12 0 66±30
13 In situþ dermal invasion 66±26 42±17 0 72±22
14 In situþ dermal invasion 48±23 22±16 0 0
15 In situþ dermal invasion 20±14 28±13 0 0
Abbreviations: ALM, acral lentiginous melanoma; pS-STAT3, signal transducer and activator of transcription 3 (STAT3) phosphorylated on Ser727;
pY-STAT3, STAT3 phosphorylated on Tyr705.
1The percentage of pS-STAT3- or pY-STAT3-positive cells in the epidermis or dermis was determined by averaging the pS-STAT3- or pY-STAT3-positive cell
counts in five randomly chosen regions of the skin section. Data are expressed as the mean±SD.
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(Burlingame, CA). TPA was purchased from Sigma (St Louis, MO).
DMSO was obtained from Nacalai Tesque (Kyoto, Japan). The MEK
inhibitor U0126 was from Sigma. The inhibitors for p38, mitogen-
activated protein kinase (SB203580), c-Jun N-terminal kinase
(SP600125), protein kinase C (GF109203X), mammalian target of
rapamycin kinase (rapamycin), cyclin-dependent kinase 5 (roscovitine),
active B-Raf (V600E) kinase (PLX4720), and JAK (JAK inhibitor I), were
purchased from Calbiochem (San Diego, CA).
Cells and cell culture
Seven human melanoma cell lines from primary (WM35, WM39,
WM98-1, and WM115) and metastatic (WM164, WM239A, and
WM1205Lu) lesions were kindly provided by Dr Meenhard Herlyn
(The Wistar Institute, Philadelphia, PA). The melanoma cell lines
were cultured in EMEM containing 5% fetal calf serum as described
previously (Oka et al., 2009). Normal human melanocytes were
obtained and maintained as described previously (Oka et al., 2007).
Where indicated, melanocytes were rendered quiescent by culturing
the cells in the absence of growth factors for 24 hours.
Western blotting
Western blotting was carried out as described previously (Oka et al.,
2007).
STAT3 siRNA
STAT3 siRNA was performed as described previously (Oka et al.,
2009) with double-stranded siRNAs against STAT3 (si-1: 50-AAC
UUCAGACCCGUCAACAAAdTdT-30; 30-dTdTGAAGUCUGGGCA
GUUGUUU-50 and si-2: AAC AUC UGC CUA GAU CGG CUA
dTdT-30 30-dTdT GUA GAC GGA UCU AGC CGA U-50).
Measurement of the DNA-binding activity of STAT3
The DNA-binding capacity of STAT3 was determined using the
TransAM STAT3 transcription factor assay kit (Active Motif,
Carlsbad, CA) according to the manufacturer’s instructions as
described previously (Oka et al., 2009).
Assay for cell survival activity
Cell survival activity was determined using a modified 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide assay
employing the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan)
according to the manufacturer’s instructions.
Immunofluorescence
Cells were seeded on Laboratory-Teck chamber slides (Nalge Nunc
International, Naperville, IL) and incubated at 37 1C with 5% CO2.
Forty-eight hours later, they were fixed for 30minutes in 4%
paraformaldehyde and permeabilized for 10minutes with ice-cold
methanol at 20 1C. The fixed cells were incubated for 1 hour in
blocking solution (5% BSA with 0.1% triton X-100 in phosphate-
buffered saline). Immunostaining was performed by incubating the
slides with rabbit polyclonal anti-pS-STAT3 (1:400) or anti-STAT3
(1:400) at 4 1C overnight, followed by Alexa fluor 488 donkey anti-
rabbit (1:100) antibody for 1 hour at room temperature. Then, stained
cells were mounted by DAPI Fluoromount G, a mounting agent
including DAPI (Southern Biotech, Birmingham, AL). Images were
captured using a Carl Zeiss LSM510 confocal microscope (Carl Zeiss
Microimage, Thornwood, NY).
Immunohistochemistry
Human melanoma tissues were obtained from patients undergoing
surgery for melanoma after their informed consent. Fifteen
specimens of ALM were pathologically divided into ALM in situ
(nine cases) and ALM with dermal invasive lesions as well as in situ
lesions (six cases). Paraffin-embedded melanoma tissues were
deparaffinized in xylene, rehydrated through graded concentrations
of ethanol and washed with phosphate-buffered saline. Endogenous
peroxidase activity was blocked with 3% H2O2 for 13minutes. For
antigen retrieval, sections were heated in 10mM sodium citrate
buffer (pH 6.0), followed by blocking with Non-Specific Staining
Blocking reagent (DakoCytomation, Carpinteria, CA). The slides
were incubated with rabbit polyclonal anti-pS-STAT3 (1:200) or anti-
pY-STAT3 (1:200) with normal rabbit IgG overnight at 4 1C. The
slides were further incubated with horseradish peroxidase-labeled
anti-rabbit polymer EnVisionþ System (DakoCytomation) at room
temperature for 25minutes. Immune complexes were visualized
with Simple Stain AEC solution (Nichirei, Tokyo, Japan), conjugated
with hematoxylin. Positive controls (using tissue samples from
human psoriasis vulgaris) and negative controls (using non-specific
rabbit antibody instead of the individual primary antibody) for pS-
STAT3 and pY-STAT3 were stained using the same procedures
(Supplementary Figure S5 online).
Statistics
Differences between results were assessed for significance using the
Student’s t-test. Po0.05 was considered to be statistically significant.
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